SCHEMBL4716637

SCHEMBL4716637

NC(=O)c1cccc(N)c1C(=O)c1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
MAPT P10636 5/20 0.47
CES2 O00748 3/20 0.46
CES1 P23141 3/20 0.46
ALOX15 P16050 1/20 0.43
GAA P10253 2/20 0.41
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PBRM1 Q86U86 1/20 0.40
PARP1 P09874 1/20 0.40
HTT P42858 1/20 0.39
BCHE P06276 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089319 0.82 MEN1 (0.48) ALDH1A1MAPTCES2CES1ALOX15
SCHEMBL23881561 0.82 MEN1 (0.48) ALDH1A1MAPTCES2CES1ALOX15
SCHEMBL5807527 0.81 MAPT (0.63) ALDH1A1MAPTGAAHPGDMEN1
SCHEMBL4710844 0.80 MAPT (0.45) ALDH1A1MAPTCES2CES1ALOX15
Water SCHEMBL27623262 0.80 CES2 (0.62) ALDH1A1MAPTCES2CES1ALOX15
SCHEMBL30089335 0.79 MAPT (0.55) ALDH1A1MAPTCES2CES1ALOX15
SCHEMBL23881551 0.79 MAPT (0.55) ALDH1A1MAPTCES2CES1ALOX15
SCHEMBL5282720 0.78 MAPT (0.59) ALDH1A1MAPTCES2CES1ALOX15
SCHEMBL29664874 0.78 MAPT (0.59) ALDH1A1MAPTCES2CES1ALOX15
SCHEMBL1512043 0.78 MMP2 (0.47) ALDH1A1MAPTGAAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268857-B2 Compositions and methods for inhibiting TGF-β MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-09-18 US disclosed
EP-1603908-B1 QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS MILLENNIUM PHARM INC (US) 2008-06-11 EP disclosed
US-20070142408-A1 Compositions and methods for inhibiting TGF-Beta MILLENNIUM PHARMACEUTICALS, INC. 2007-06-21 US disclosed
US-7189733-B2 Compositions and methods for inhibiting TGF-β MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-03-13 US disclosed
EP-1603908-A1 QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-12-14 EP disclosed
US-20040204431-A1 Compositions and methods for inhibiting TGF-beta MILLENNIUM PHARMACEUTICALS, INC. 2004-10-14 US disclosed
WO-2004081009-A1 QUINAZOLINE DERIVATIVES AS TGF-BETA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204431-A1 Compositions and methods for inhibiting TGF-beta TGFB1, TGFBR2, TGFB2 ALDH1A1 2279/4885MAPT 3416/4885CES2 2426/4885
US-20070142408-A1 Compositions and methods for inhibiting TGF-Beta TGFB1, TGFB2, TGFBR1 ALDH1A1 1594/4885MAPT 2547/4885CES2 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.